Form 8-K - Current report:
SEC Accession No. 0001140361-25-004957
Filing Date
2025-02-18
Accepted
2025-02-18 06:01:21
Documents
15
Period of Report
2025-02-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ny20043721x1_8k.htm   iXBRL 8-K 28171
2 EXHIBIT 99.1 ny20043721x1_ex99-1.htm EX-99.1 469753
6 ny20043721x1_ex99-1img01.jpg GRAPHIC 24061
  Complete submission text file 0001140361-25-004957.txt   711571

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA gyre-20250214.xsd EX-101.SCH 4024
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE gyre-20250214_lab.xml EX-101.LAB 21966
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE gyre-20250214_pre.xml EX-101.PRE 16072
18 EXTRACTED XBRL INSTANCE DOCUMENT ny20043721x1_8k_htm.xml XML 4040
Mailing Address 12770 HIGH BLUFF DRIVE, SUITE 150 SAN DIEGO CA 92130
Business Address 12770 HIGH BLUFF DRIVE, SUITE 150 SAN DIEGO CA 92130 (619) 949-3681
GYRE THERAPEUTICS, INC. (Filer) CIK: 0001124105 (see all company filings)

EIN.: 562020050 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-51173 | Film No.: 25632389
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)